Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
A new seven-point plan to strengthen America’s biotechnology leadership amid intensifying global competition from China was released by the Biotechnology Innovation Organization (BIO) on […]
BioAdvance: BIO releases national action plan to strengthen US biotech leadership Read More »
Orphan drug development is one of the more fraught undertakings in biomedical research. Targeting rare diseases often requires cutting-edge science, but science is not
The latest portrait of America’s biotech industry describes a growing economic force responsible for $3.19 trillion in total U.S. economic output and employment of
2026 report on biotech’s economic impact portrays a vast ecosystem Read More »
BIO’s comments advise strengthening communication and clarity of recommendations, and maintaining access. The Advisory Committee on Immunization Practices (ACIP) should remain the body responsible
BIO supports retaining current vaccine recommendation categories Read More »
There are a lot of reasons to be skeptical of the HHS effort to bring international reference prices into Medicare via the proposed GLOBE
On Tuesday July 28, the Arkansas State Board of Pharmacy suspended enforcement of a 2025 Arkansas law, Act 630, two months after a federal
Following court decision, Arkansas will not enforce Act 630 on drug distribution Read More »
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) will consider this week whether seven unapproved peptides should be added to the Section 503A Bulk Drug
FDA Advisory Committee to weigh whether to expand compounding of unapproved peptides Read More »
The Reagan-Udall Foundation for the FDA just released a new report on strengthening early-stage drug development in the United States. The report reflects insights
New report details how U.S. can maintain biotech competitiveness Read More »
Researchers utilize health data to inform medical breakthroughs, but patients need to know their personal information stays confidential. The current patchwork of state laws
House hearing to examine bill balancing data privacy and R&D needs Read More »
The Administration’s Council of Economic Advisors (CEA) has released an analysis of savings expected from its “Most Favored Nation” deals with pharmaceutical manufacturers, but
Exaggerated MFN cost-saving estimates imperil U.S. innovation and investment Read More »
